Latest News and Press Releases

Company announcement – No. 37 / 2023 Zealand Pharma major shareholder announcement: Polar Capital Copenhagen, Denmark, 20 October 2023 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20...

Press release – No. 13 / 2023 Zealand Pharma presents data for amylin analog ZP8396 at ObesityWeek Copenhagen, Denmark, October 17, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no....

Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease Press release – No. 12 /...

Company announcement – No. 36 / 2023 Total number of shares and voting rights in Zealand Pharma at September 29, 2023 Copenhagen, Denmark, September 29, 2023 – Zealand Pharma A/S (“Zealand”)...

Company announcement – No. 35 / 2023 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...

Company announcement – No. 34 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, September 14, 2023 – Zealand Pharma A/S...

Press release – No. 11 / 2023 SAVE THE DATE: Zealand Pharma to host Obesity R&D Event in London on December 5, 2023 Copenhagen, Denmark, September 8, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL)...

Press release – No. 10 / 2023 Zealand Pharma to participate in upcoming healthcare conferences in September 2023 Copenhagen, Denmark, September 7, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL)...

Company announcement – No. 33 / 2023 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...

Company announcement – No. 32 / 2023  Copenhagen, Denmark, August 31, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on...